FDA Grants Priority Review for Kura Oncology, Inc. (KURA) and Kyowa Kirin’s Ziftomenib
The U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for ziftomenib, an investigational treatment pursued by Kura Oncology, Inc.
Kura Oncology Inc. (KURA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Biotechnology Value Fund / BVF Inc Mark Lampert | 7,754,129 | $51,177,251 | +203% | 2.09% |
| 2. | Suvretta Capital Management Aaron Cowen | 7,439,259 | $49,099,109 | +47% | 1.82% |
| 3. | Armistice Capital Steven Boyd | 6,572,000 | $43,375,200 | +14% | 0.65% |
| 4. | RA Capital Management Peter Kolchinsky | 4,004,610 | $26,430,426 | -11% | 0.44% |
| 5. | EcoR1 Capital Oleg Nodelman | 2,640,298 | $17,425,967 | -26% | 1.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.50 | 50,000 | $575,000.00 | 139,557 | 2023-06-16 | Filing | |
| $13.16 | 83,540 | $1,099,386.40 | 4,408,097 | 2018-12-21 | Filing | |
| $13.84 | 51,879 | $718,005.36 | 4,324,557 | 2018-12-19 | Filing | |
| $13.82 | 78,469 | $1,084,441.58 | 4,272,678 | 2018-12-18 | Filing | |
| $13.89 | 25,217 | $350,264.13 | 4,220,729 | 2018-12-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.96 | 1,559 | $9,291.64 | 107,948 | 2025-05-19 | Filing | |
| $6.28 | 1,558 | $9,777.38 | 21,367 | 2025-05-19 | Filing | |
| $8.00 | 22,682 | $181,456.00 | 23,983 | 2025-03-21 | Filing | |
| $7.87 | 1,122 | $8,832.27 | 88,193 | 2025-01-28 | Filing | |
| $7.87 | 699 | $5,502.46 | 89,315 | 2025-01-28 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,177,646 | $53,972,463 | 0% | |
| 2. | 4,948,235 | $32,658,352 | 0% | |
| 3. | 3,282,080 | $21,661,728 | 0% | |
| 4. | 1,923,158 | $12,692,843 | 0% | |
| 5. | 1,802,559 | $11,899,766 | 0% |
News See All
Kura Oncology, Inc. (NASDAQ:KURA) Q1 2025 Earnings Call Transcript
Operator: Good day everyone and welcome to today’s First Quarter 2025 Kura Oncology Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2024 Earnings Call Transcript
Operator: Good day, everyone, and welcome to today's Q4 2024 Kura Oncology, Inc. Financial Results Conference Call. At this time, all participants are in a listen-only mode.
10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
The biotechnology sector is expanding quickly due to rising demand for novel therapies, technological advances, and government assistance.
10 Most Promising Cancer Stocks According to Hedge Funds
According to the World Health Organization (WHO), cancer remains one of the leading causes of death globally, responsible for nearly 10 million deaths in 2020, or about one in six deaths worldwide.
Kura Oncology, Inc. (NASDAQ:KURA) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen. Welcome to the Kura Oncology Third Quarter 2024 Financial Results Call. At this time, all participants are in a listen-only mode.
10 Best Small-Cap Healthcare Stocks To Buy Now
In difficult economic times, healthcare equities are sometimes regarded as a defensive investment.
Kura Oncology, Inc. (NASDAQ:KURA) Q2 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Q2 2024 Kura Oncology Conference Call. [Operator Instructions] Please note this event is being recorded.
Kura Oncology, Inc. (NASDAQ:KURA) Q1 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Q1 2024 Kura Oncology Financial Results Conference Call. At this time, all participants are in listen-only mode.